Pfizer: FDA Approves Xeljanz to Treat Active Polyarticular Course Juvenile Idiopathic Arthritis
September 28 2020 - 7:03PM
Dow Jones News
By Stephen Nakrosis
Pfizer Inc. on Monday said the U.S. Food and Drug Administration
approved its Xeljanz to treat children and adolescents 2 years and
older with active polyarticular course juvenile idiopathic
arthritis.
The company said two formulations of Xeljanz, or tofacitinib,
were approved by the FDA, one a tablet and the other an oral
solution. The company also said 5 mg tablets will be available
immediately, while the oral solution is expected to be available by
the end of the first quarter of next year.
Pfizer said the approval "makes Xeljanz the first and only Janus
kinase inhibitor approved in the U.S. for the treatment of
pcJIA."
According to Pfizer, Juvenile idiopathic arthritis is a chronic
inflammatory disease that affects about 300,000 children in the
U.S. "Polyarticular JIA is characterized by arthritis in five or
more joints and affects both the small joints of the hands and
feet, and large joints like the knees, hips and ankles," Pfizer
said.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
September 28, 2020 18:48 ET (22:48 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024